Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Nancy Dvorin
Free: In Vivo welcomes contributions from thought leaders in the life sciences industry. We've posted some guidelines to help you get started.
Free article: In Vivo's editors pick March's most significant deals, including Spero's Series C and Allergan's deal with Editas.
Free content: There were 132 personalized medicines on the market in 2016, compared with just five in in 2008, according to the Personalized Medicine Coalition. And 27% of new molecular entities approved by the FDA in 2016 can be can be classified as a personalized medicine. That's a big jump from 2005, when personalized medicines accounted for just 5% of NME approvals. A look at some other key numbers in this rapidly growing field.
Free article: What In Vivo has been saying about personalized medicine in this century.
Free article: In Vivo's editors pick February's most significant deals, including Seattle Genetics' new ADC and Integra's big bid in neurosurgery.
In Vivo's editors pick January's most significant deals, including J&J's Actelion acquisition and a big launch for Vir Biotechnology. (Article free with registration.)